Neuropathic pain

Last updated
Neuropathic pain
Specialty Neurology and psychiatry
DurationVariable
CausesDamage to the nervous system resulting from diabetes mellitus, multiple sclerosis, infection, injury, and stroke, among others
Risk factors Diabetes mellitus; multiple sclerosis; exposure to neurotoxicants; alcoholism; history of chemo- and/or radiotherapy; & nutritional deficiencies, among others
Diagnostic method Clinical interview; quantitative sensory testing; electroneuromyography; nerve stimulation; biopsy; imaging, & patient self-rating of symptoms
Differential diagnosis Diabetic and metabolic neuropathy; demyelinating disease (e.g., multiple sclerosis); malignancy; spinal cord injury; primary neuralgia; mononeuritis multiplex; sciatica; pruritic processes; fibromyalgia; and functional pain syndrome, among others
Treatment Physical therapy; exercise; psychotherapy; antidepressants; gabapentinoids; anticonvulsants; Tramadol; neuromodulation, and topical agents, among others
Frequency4.1%-12.4% (12-month prevalence, US adults) [1]

Neuropathic pain is pain caused by a lesion or disease of the somatosensory nervous system. [2] [3] Neuropathic pain may be associated with abnormal sensations called dysesthesia or pain from normally non-painful stimuli (allodynia). It may have continuous and/or episodic (paroxysmal) components. The latter resemble stabbings or electric shocks. Common qualities include burning or coldness, "pins and needles" sensations, numbness and itching. [3]

Contents

Up to 7–8% of the European population is affected by neuropathic pain, [4] and in 5% of persons it may be severe. [5] [6] The pain may result from disorders of the peripheral nervous system or the central nervous system (brain and spinal cord). Neuropathic pain may occur in isolation or in combination with other forms of pain. Medical treatments focus on identifying the underlying cause and relieving pain. In cases of peripheral neuropathy, the pain may progress to insensitivity.

Diagnosis

Quantitative sensory testing may assist with diagnosis of specific deficits

Diagnosis of pain conditions relies on the character of the pain with a sharp stabbing character and the presence of particular features such as mechanical allodynia and cold allodynia. Neuropathic pain also tends to affect defined dermatomes and there may be limits to the area of pain. For neuropathic pain, clinicians look for an underlying lesion to the nervous system or an inciting cause consistent with the development of neuropathic pain. The obvious presence of an underlying feature or cause is not always detectable, and response to treatment may be used as a surrogate particularly in cases where diagnosis of the underlying lesion leaves the patient in pain for a prolonged period of time. MRI may be helpful in the identification of underlying lesions, reversible causes or serious underlying conditions such as primary presentation of a tumor or multiple sclerosis. Quantitative sensory testing (QST), a system of detailed analysis of the somatosensory system, is frequently used in research situations to identify neuropathic pain and a more detailed analysis of its components. It has been suggested by some authorities that QST may have a future role in the diagnosis of neuropathic pain and in particular the identification of neuropathic pain subtypes. Neuropathic pain can occur alone or in combination with other types of pain. The identification of neuropathic pain components is important as different classes of analgesic are required. [7]

The gold standard for diagnosing small fiber neuropathy as the etiology of neuropathic pain is skin biopsy. Sudomotor assessment, through electrochemical skin conductance, an accurate objective technique, could be considered as a good screening tool to limit skin biopsy in patients in whom it is not suitable. [8] [9]

Causes

Neuropathic pain may be divided into peripheral, central or mixed (peripheral and central) types. Central neuropathic pain is found in spinal cord injury [10] and multiple sclerosis. [11] Peripheral neuropathies are commonly caused by diabetes, metabolic disorders, herpes zoster infection, HIV-related neuropathies, nutritional deficiencies, toxins, remote manifestations of malignancies, immune mediated disorders and physical trauma to a nerve trunk. [12] [13] Neuropathic pain is common in cancer as a direct result of cancer on peripheral nerves (e.g., compression by a tumor), or as a side effect of chemotherapy (chemotherapy-induced peripheral neuropathy), [14] [15] radiation injury or surgery. [3]

Comorbidities

Neuropathic pain has profound physiological effects on the brain which can manifest as psychological disorders. Rodent models where the social effects of chronic pain can be isolated from other factors suggest that induction of chronic pain can cause anxio-depressive symptoms and that particular circuits in the brain have a direct connection. [16] [17] Depression and neuropathic pain may have a bidirectional relationship and relief of co-morbid depression may underlie some of the therapeutic efficacy of antidepressants in neuropathic pain. Neuropathic pain has important effects on social well-being that should not be ignored. People with neuropathic pain may have difficulty working exhibiting higher levels of presenteeism, absenteeism and unemployment, [18] exhibit higher levels of substance misuse (which may be related to attempted self-medication), [19] [20] and present difficulties with social interactions. [21] Moreover, uncontrolled neuropathic pain is a significant risk factor for suicide. [22] Certain classes of neuropathic pain may cause serious adverse effects necessitating hospital admission, for instance trigeminal neuralgia can present as a severe crisis where the patient may have difficulty talking, eating and drinking. [23] As neuropathic pain may be comorbid with cancer, it can have important dose limiting effects on certain classes of chemotherapeutic. [24]

Treatments

Neuropathic pain can be very difficult to treat with only some 40-60% of people achieving partial relief. [25]

General approach

First line treatments are certain antidepressants (tricyclic antidepressants and serotonin–norepinephrine reuptake inhibitors), and anticonvulsants (pregabalin and gabapentin). [26] [27] Opioid analgesics are recognized as useful agents but are not recommended as first line treatments. [27] A broader range of treatments are used in specialist care. There are limited data and guidance for the long-term treatment of pain. Notably, strong evidence from randomized controlled trials is not available for all interventions.[ citation needed ]

Primary interventions

Anticonvulsants

Pregabalin and gabapentin may reduce pain associated with diabetic neuropathy. [28] [26] [29] [30] The anticonvulsants carbamazepine and oxcarbazepine are especially effective in trigeminal neuralgia. Carbamazepine is a voltage-gated sodium channel inhibitor, and reduces neuronal excitability by preventing depolarisation. [31] Carbamazepine is most commonly prescribed to treat trigeminal neuralgia due to clinical experience and early clinical trials showing strong efficacy. Gabapentin may reduce symptoms associated with neuropathic pain or fibromyalgia in some people. [26] There is no predictor test to determine if it will be effective for a particular person. A short trial period of gabapentin therapy is recommended, to determine the effectiveness for that person. 62% of people taking gabapentin may have at least one adverse event, however the incidence of serious adverse events was found to be low. [26]

Meta analysis of randomized clinical trials suggests that Lamotrigine is not useful for the majority of patients although it may have use in treatment refractory cases. [32]

Antidepressants

Dual serotonin-norepinephrine reuptake inhibitors in particular duloxetine, as well as tricyclic antidepressants in particular amitriptyline, and nortriptyline are considered first-line medications for this condition. [27]

Opioids

Opioids, while commonly used in chronic neuropathic pain, are not a recommended first or second line treatment. [33] In the short and long term they are of unclear benefit, although clinical experience suggests that opioids like tramadol may be useful for treating sudden onset severe pain [34] In the intermediate term evidence of low quality supports utility. [34]

Several opioids, particularly levorphanol, methadone and ketobemidone, possess NMDA receptor antagonism in addition to their μ-opioid agonist properties. Methadone does so because it is a racemic mixture; only the l-isomer is a potent μ-opioid agonist. The d-isomer does not have opioid agonist action and acts as an NMDA receptor antagonist; d-methadone is analgesic in experimental models of chronic pain. [35]

There is little evidence to indicate that one strong opioid is more effective than another. Expert opinion leans toward the use of methadone for neuropathic pain, in part because of its NMDA antagonism. It is reasonable to base the choice of opioid on other factors. [36] It is unclear if fentanyl gives pain relief to people with neuropathic pain. [37] The potential pain relief benefits of strong opioids must be weighed against their significant addiction potential under normal clinical use and some authorities suggest that they should be reserved for cancer pain. [38] Importantly, recent observational studies suggest a pain-relief benefit in non-cancer related chronic pain of reducing or terminating long-term opioid therapy. [39] [40]

Non-Pharmaceutical Interventions

Non-pharmaceutical treatments such as exercise, physical therapy and psychotherapy may be useful adjuncts to treatment. [41]

Secondary and research interventions

Botulinum toxin type A

Local intradermal injection of botulinum neurotoxin type A may be helpful in chronic focal painful neuropathies. However, it causes muscle paralysis which may impact quality of life. [42]

Cannabinoids

Evidence for the use of Cannabis based medicines is limited. Any potential utility might be offset by adverse effects. [43]

Neuromodulators

Neuromodulation is a field of science, medicine and bioengineering that encompasses both implantable and non-implantable technologies (electrical and chemical) for treatment purposes. [44]

Implanted devices are expensive and carry the risk of complications. Available studies have focused on conditions having a different prevalence than neuropathic pain patients in general. More research is needed to define the range of conditions that they might benefit.

Deep brain stimulation

The best long-term results with deep brain stimulation have been reported with targets in the periventricular/periaqueductal grey matter (79%), or the periventricular/periaqueductal grey matter plus thalamus and/or internal capsule (87%). [45] There is a significant complication rate, which increases over time. [46]

Motor cortex stimulations

Stimulation of the primary motor cortex through electrodes placed within the skull but outside the thick meningeal membrane (dura) has been used to treat pain. The level of stimulation is below that for motor stimulation. As compared with spinal stimulation, which is associated with noticeable tingling (paresthesia) at treatment levels, the only palpable effect is pain relief. [47] [48]

Spinal cord stimulators implated spinal pumps

Spinal cord stimulators use electrodes placed adjacent to but outside the spinal cord. The overall complication rate is one-third, most commonly due to lead migration or breakage but advancements in the past decade have driven complication rates much lower. Lack of pain relief occasionally prompts device removal. [49]

NMDA antagonism

The N-methyl-D-aspartate (NMDA) receptor seems to play a major role in neuropathic pain and in the development of opioid tolerance. Dextromethorphan is an NMDA antagonist at high doses. Experiments in both animals and humans have established that NMDA antagonists such as ketamine and dextromethorphan can alleviate neuropathic pain and reverse opioid tolerance. [50] Unfortunately, only a few NMDA antagonists are clinically available and their use is limited by a very short half life (ketamine), weak activity (memantine) or unacceptable side effects (dextromethorpan).

Intrathecal drug delivery

Intrathecal pumps deliver medication to the fluid filled (subarachnoid) space surrounding the spinal cord. Opioids alone or opioids with adjunctive medication (either a local anesthetic or clonidine). Rarely there are complications such as serious infection (meningitis), urinary retention, hormonal disturbance and intrathecal granuloma formation have been noted with intrathecal infusion, associated with the delivery method.

Photopharmacology

Photoswitchable analogues of the anticonvulsant drug carbamazepine have been developed to control its pharmacological activity locally and on demand using light, with the purpose to reduce adverse systemic effects. [51] One of these compounds (carbadiazocine, based on a bridged azobenzene) has been shown to produce analgesia with noninvasive illumination in a rat model of neuropathic pain.

Conotoxins

Ziconotide is a voltage-gated calcium channel blocker which may be used in severe cases of ongoing neuropathic pain [52] it is delivered intrathecally.

Ambroxol

Ambroxol is a drug that reduces mucus. Preclinical research suggests it may produce analgesic effects by blocking sodium channels in sensory neurons. [53]

Gene therapy

The use of gene therapy is a potential treatment for chronic neuropathic pain. [54] In animals a gene therapy for local transgenes encoding for GABA synthesizing-releasing inhibitory machinery has been demonstrated and was effective for months at a time. It increases synaptically GABA-mediated neuronal inhibition in the spinal cord (or in the brain) via the induced expression of genes GAD65 and VGAT without any detected systemic or segmental side effects. [54]

Topical agents

In some forms of neuropathy the topical application of local anesthetics such as lidocaine may provide relief. A transdermal patch containing lidocaine is available commercially in some countries.

Repeated topical applications of capsaicin are followed by a prolonged period of reduced skin sensibility referred to as desensitization, or nociceptor inactivation. Capsaicin causes reversible degeneration of epidermal nerve fibers. [55] Notably the capsaicin used for the relief of neuropathic pain is a substantially higher concentration than capsaicin creams available over the counter, there is no evidence that over the counter capsaicin cream can improve neuropathic pain [56] and topical capsaicin can itself induce pain. [55]

Surgical interventions

Orthopaedic interventions are frequently used to correct underlying pathology which may contribute to neuropathic pain. Many orthopaedic procedures have more limited evidence. Historically, neurosurgeons have attempted lesions of regions of the brain, spinal cord and peripheral nervous system. Whilst they cause some short term analgesia, these are considered to be universally ineffective.[ citation needed ]

If neuropathic pain is caused by nerve compression, this may be treatable with a nerve decompression. [57] [58] [59] [60] [61] When nerves are subject to chronic pressure, they exhibit a pathological progression resulting in reversible and partially reversible nerve injuries that cause pain, paresthesias, and potentially muscle weakness. [62] In a nerve decompression, a surgeon explores the entrapment site and removes tissue around the nerve to relieve pressure. [57] In many cases the potential for nerve recovery (full or partial) after decompression is excellent, as chronic nerve compression is associated with low-grade nerve injury (Sunderland classification I-III) rather than high-grade nerve injury (Sunderland classification IV-V). [63] Nerve decompressions are associated with a significant reduction in pain, in some cases the complete elimination of pain. [64] [58] [59]

For patients with diabetic peripehral neuropathy (which affects 30% of diabetes patients [65] ) and superimposed nerve compression, this may be treatable with multiple nerve decompressions. [66] [67] The theory behind this procedure is that diabetic peripheral neuropathy (DPN) predisposes peripheral nerves to compression at anatomic sites of narrowing, and that the majority of peripheral DPN symptoms may actually be attributable to nerve compression rather than DPN itself. [68] [69] [70] The surgery is associated with lower pain scores, higher two-point discrimination (a measure of sensory improvement), lower rate of ulcerations, fewer falls (in the case of lower extremity decompression), and fewer amputations. [69] [71] [66] [67]

Alternative therapies

Herbal products

There is no good evidence that herbal products (nutmeg or St John's wort) are useful for treating neuropathic pain. [72]

Dietary supplements

A 2007 review of studies found that injected (parenteral) administration of alpha lipoic acid (ALA) was found to reduce the various symptoms of peripheral diabetic neuropathy. [73] While some studies on orally administered ALA had suggested a reduction in both the positive symptoms of diabetic neuropathy (dysesthesia including stabbing and burning pain) as well as neuropathic deficits (paresthesia), [74] the meta-analysis showed "more conflicting data whether it improves sensory symptoms or just neuropathic deficits alone". [73] There is some limited evidence that ALA is also helpful in some other non-diabetic neuropathies. [75]

Benfotiamine is an oral prodrug of Vitamin B1 that has several placebo-controlled double-blind trials proving efficacy in treating neuropathy and various other diabetic comorbidities. [76] [77]

History

The history of pain management can be traced back to ancient times. Galen also suggested nerve tissue as the transferring route of pain to the brain through the invisible psychic pneuma. [78] The idea of origination of pain from the nerve itself, without any exciting pathology in other organs is presented by medieval medical scholars such as Rhazes, Haly Abbas and Avicenna. They named this type of pain specifically as "vaja al asab" [nerve originated pain], described its numbness, tingling and needling quality, discussed its etiology and the differentiating characteristics. [79] The description of neuralgia was made by John Fothergill (1712-1780). In a medical article entitled "Clinical Lecture on Lead Neuropathy" published in 1924 the word "Neuropathy" was used for the first time by Gordon. [80]

Proposed mechanistic basis for neuropathic pain

The underlying pathophysiology of neuropathic pain remains a contested topic. The etiology and mechanism of pain are related to the cause of the pain. Certain forms of neuropathic pain are associated with lesions to the central nervous system such as thalamic pain associated with certain lesions (for instance strokes) to the thalamus [81] whereas other forms of pain have a peripheral inciting injury such as traumatic neuropathies. [10] The inciting cause of neuropathy has important consequences for its mechanistic basis as different tissues and cells are involved. The mechanistic basis of neuropathic pain remains controversial as do the relative contributions of each pathway. Notably our understanding of these processes is largely driven by rodent models in part because studying these tissues in living adults is difficult.

Peripheral

With peripheral nervous system lesions, a number of processes may occur. Intact neurons may become unusually sensitive and develop spontaneous pathological activity and abnormal excitability.

During neuropathic pain, ectopic activity arises in the peripheral nociceptors and this appears to be due in part to changes in the ion channel expression at the level of the periphery. There may be an increase in the expression or activity of voltage gated sodium and calcium channels which will support action potential generation. There may also be a decrease in potassium channels which would normally oppose action potential generation. Each of these changes appears to support an increase in excitability, which may allow endogenous stimuli to cause spontaneous pain. [82]

Central

Central mechanisms of neuropathic pain involve a number of major pathways. Nociception is ordinarily transduced by a polysynaptic pathway through the spinal cord, and up the spinothalamic tract to the thalamus and then the cortex. Broadly speaking in neuropathic pain, neurons are hypersensitized, glia become activated and there is a loss of inhibitory tone.

Pain gates

Gate control theory of pain Gate control A firing.svg
Gate control theory of pain

A major hypothesis in the theory of pain perception is the gate control theory of pain, proposed by Wall and Melzack in 1965. The theory predicts that the activation of central pain inhibitory neurons by non-pain sensing neurons prevents the transmission of non-harmful stimuli to pain centers in the brain. A loss of inhibitory neurons, GAD65/67 expression (the enzymes that synthesise GABA; the predominant inhibitory transmitter in the adult brain), has been observed in some systems following peripheral neuropathy such as in rats, and mice. [83] However, these observations remain controversial with some investigators unable to detect a change. The loss of inhibitory inputs may allow fibers to transmit messages via the spinothalamic tract thus causing pain in normally painless stimuli. This loss of inhibition may not be limited to the spinal cord and a loss of GABA has also been observed in chronic pain patients in the thalamus. [84]

Glia

Microglia (identified by alpha-coronin1a), and neurons in culture. Microglia are proposed to release molecules that alter the excitability of neurons. Microglia and neurons.jpg
Microglia (identified by alpha-coronin1a), and neurons in culture. Microglia are proposed to release molecules that alter the excitability of neurons.

During neuropathic pain, glia become "activated" leading to the release of proteins that modulate neural activity. The activation of glia remains an area of intense interest for researchers. Microglia, the brain and spinal cord resident immune cells, respond to extrinsic cues. The source of these cues may include neurons secreting chemokines such as CCL21 and surface immobilized chemokines such as CX3CL1. Other glia such as astrocytes and oligodendrocytes may also release these extrinsic cues for microglia and microglia themselves may produce proteins that amplify the response. [85] The effect of microglia on neurons that leads to the neurons being sensitized is controversial. Brain derived neurotrophic factor, prostaglandins, TNF and IL-1β may be produced by microglia and cause changes in neurons that lead to hyperexcitability. [86] [87]

Central sensitization

Central sensitization is a potential component of neuropathic pain. It refers to a change in synaptic plasticity, efficacy, and intrinsic disinhibition that leads to an uncoupling of noxious inputs. In the sensitized neuron, outputs are no longer coupled to the intensity or duration and many inputs may be combined. [88]

Circuit Potentiation

During high frequency stimulation synapses conveying nociceptive information may become hyper efficient in a process that is similar although not identical to long-term potentiation. [89] Molecules such as substance P may be involved in potentiation via neurokinin receptors. NMDA activation also triggers a change in the post synapse, it activates receptor kinases that increase receptor trafficking and post-translationally modify receptors causing changes in their excitability. [88]

Cellular

The phenomena described above are dependent on changes at the cellular and molecular levels. Altered expression of ion channels, changes in neurotransmitters and their receptors, as well as altered gene expression in response to neural input, are at play. [90] Neuropathic pain is associated with changes in sodium and calcium channel subunit expression resulting in functional changes.  In chronic nerve injury, there is redistribution and alteration of subunit compositions of sodium and calcium channels resulting in spontaneous firing at ectopic sites along the sensory pathway. [13]

See also

Related Research Articles

<span class="mw-page-title-main">Pain</span> Type of distressing feeling

Pain is a distressing feeling often caused by intense or damaging stimuli. The International Association for the Study of Pain defines pain as "an unpleasant sensory and emotional experience associated with, or resembling that associated with, actual or potential tissue damage."

Chronic pain or chronic pain syndrome is a type of pain that is also known by other titles such as gradual burning pain, electrical pain, throbbing pain, and nauseating pain. This type of pain is sometimes confused with acute pain and can last from three months to several years; various diagnostic manuals such as DSM-5 and ICD-11 have proposed several definitions of chronic pain, but the accepted definition is that it is "pain that lasts longer than the expected period of recovery."

<span class="mw-page-title-main">Trigeminal neuralgia</span> Neurological pain disorder

Trigeminal neuralgia, also called Fothergill disease, tic douloureux, trifacial neuralgia, or suicide disease, is a long-term pain disorder that affects the trigeminal nerve, the nerve responsible for sensation in the face and motor functions such as biting and chewing. It is a form of neuropathic pain. There are two main types: typical and atypical trigeminal neuralgia.

Pudendal nerve entrapment (PNE), also known as Alcock canal syndrome, is an uncommon source of chronic pain in which the pudendal nerve is entrapped or compressed in Alcock's canal. There are several different types of PNE based on the site of entrapment anatomically. Pain is positional and is worsened by sitting. Other symptoms include genital numbness, fecal incontinence and urinary incontinence.

Diabetic neuropathy includes various types of nerve damage associated with diabetes mellitus. The most common form, diabetic peripheral neuropathy, affects 30% of all diabetic patients. Symptoms depend on the site of nerve damage and can include motor changes such as weakness; sensory symptoms such as numbness, tingling, or pain; or autonomic changes such as urinary symptoms. These changes are thought to result from a microvascular injury involving small blood vessels that supply nerves. Relatively common conditions which may be associated with diabetic neuropathy include distal symmetric polyneuropathy; third, fourth, or sixth cranial nerve palsy; mononeuropathy; mononeuropathy multiplex; diabetic amyotrophy; and autonomic neuropathy.

<span class="mw-page-title-main">Peripheral neuropathy</span> Nervous system disease affecting nerves beyond the brain and spinal cord

Peripheral neuropathy, often shortened to neuropathy, refers to damage or disease affecting the nerves. Damage to nerves may impair sensation, movement, gland function, and/or organ function depending on which nerve fibers are affected. Neuropathies affecting motor, sensory, or autonomic nerve fibers result in different symptoms. More than one type of fiber may be affected simultaneously. Peripheral neuropathy may be acute or chronic, and may be reversible or permanent.

<span class="mw-page-title-main">Hyperalgesia</span> Abnormally increased sensitivity to pain

Hyperalgesia is an abnormally increased sensitivity to pain, which may be caused by damage to nociceptors or peripheral nerves and can cause hypersensitivity to stimulus. Prostaglandins E and F are largely responsible for sensitizing the nociceptors. Temporary increased sensitivity to pain also occurs as part of sickness behavior, the evolved response to infection.

Postherpetic neuralgia (PHN) is neuropathic pain that occurs due to damage to a peripheral nerve caused by the reactivation of the varicella zoster virus. PHN is defined as pain in a dermatomal distribution that lasts for at least 90 days after an outbreak of herpes zoster. Several types of pain may occur with PHN including continuous burning pain, episodes of severe shooting or electric-like pain, and a heightened sensitivity to gentle touch which would not otherwise cause pain or to painful stimuli. Abnormal sensations and itching may also occur.

Neuralgia is pain in the distribution of a nerve or nerves, as in intercostal neuralgia, trigeminal neuralgia, and glossopharyngeal neuralgia.

<span class="mw-page-title-main">Allodynia</span> Feeling of pain from stimuli which do not normally elicit pain

Allodynia is a condition in which pain is caused by a stimulus that does not normally elicit pain. For example, sunburn can cause temporary allodynia, so that usually painless stimuli, such as wearing clothing or running cold or warm water over it, can be very painful. It is different from hyperalgesia, an exaggerated response from a normally painful stimulus. The term comes from Ancient Greek άλλος (állos) 'other' and οδύνη (odúnē) 'pain'.

A neurectomy, or nerve resection is a neurosurgical procedure in which a peripheral nerve is cut or removed to alleviate neuropathic pain or permanently disable some function of a nerve. The nerve is not intended to grow back. For chronic pain it may be an alternative to a failed nerve decompression when the target nerve has no motor function and numbness is acceptable. Neurectomies have also been used to permanently block autonomic function, and special sensory function not related to pain.

<span class="mw-page-title-main">Group C nerve fiber</span> One of three classes of nerve fiber in the nervous system

Group C nerve fibers are one of three classes of nerve fiber in the central nervous system (CNS) and peripheral nervous system (PNS). The C group fibers are unmyelinated and have a small diameter and low conduction velocity, whereas Groups A and B are myelinated. Group C fibers include postganglionic fibers in the autonomic nervous system (ANS), and nerve fibers at the dorsal roots. These fibers carry sensory information.

<span class="mw-page-title-main">Atypical trigeminal neuralgia</span> Medical condition

Atypical trigeminal neuralgia (ATN), or type 2 trigeminal neuralgia, is a form of trigeminal neuralgia, a disorder of the fifth cranial nerve. This form of nerve pain is difficult to diagnose, as it is rare and the symptoms overlap with several other disorders. The symptoms can occur in addition to having migraine headache, or can be mistaken for migraine alone, or dental problems such as temporomandibular joint disorder or musculoskeletal issues. ATN can have a wide range of symptoms and the pain can fluctuate in intensity from mild aching to a crushing or burning sensation, and also to the extreme pain experienced with the more common trigeminal neuralgia.

<span class="mw-page-title-main">Wide dynamic range neuron</span>

The wide dynamic range (WDR) neuron was first discovered by Mendell in 1966. Early studies of this neuron established what is known as the gate control theory of pain. The basic concept is that non-painful stimuli block the pathways for painful stimuli, inhibiting possible painful responses. This theory was supported by the fact that WDR neurons are responsible for responses to both painful and non-painful stimuli, and the idea that these neurons could not produce more than one of these responses simultaneously. WDR neurons respond to all types of somatosensory stimuli, make up the majority of the neurons found in the posterior grey column, and have the ability to produce long range responses including those responsible for pain and itch.

<span class="mw-page-title-main">Nerve compression syndrome</span> Human medical condition

Nerve compression syndrome, or compression neuropathy, or nerve entrapment syndrome, is a medical condition caused by chronic, direct pressure on a peripheral nerve. It is known colloquially as a trapped nerve, though this may also refer to nerve root compression. Its symptoms include pain, tingling, numbness and muscle weakness. The symptoms affect just one particular part of the body, depending on which nerve is affected. The diagnosis is largely clinical and can be confirmed with diagnostic nerve blocks. Occasionally imaging and electrophysiology studies aid in the diagnosis. Timely diagnosis is important as untreated chronic nerve compression may cause permanent damage. A surgical nerve decompression can relieve pressure on the nerve but cannot always reverse the physiological changes that occurred before treatment. Nerve injury by a single episode of physical trauma is in one sense an acute compression neuropathy but is not usually included under this heading, as chronic compression takes a unique pathophysiological course.

<span class="mw-page-title-main">Rostral ventromedial medulla</span> Group of neurons in medulla of brain

The rostral ventromedial medulla (RVM), or ventromedial nucleus of the spinal cord, is a group of neurons located close to the midline on the floor of the medulla oblongata. The rostral ventromedial medulla sends descending inhibitory and excitatory fibers to the dorsal horn spinal cord neurons. There are 3 categories of neurons in the RVM: on-cells, off-cells, and neutral cells. They are characterized by their response to nociceptive input. Off-cells show a transitory decrease in firing rate right before a nociceptive reflex, and are theorized to be inhibitory. Activation of off-cells, either by morphine or by any other means, results in antinociception. On-cells show a burst of activity immediately preceding nociceptive input, and are theorized to be contributing to the excitatory drive. Neutral cells show no response to nociceptive input.

Neuromodulation is "the alteration of nerve activity through targeted delivery of a stimulus, such as electrical stimulation or chemical agents, to specific neurological sites in the body". It is carried out to normalize – or modulate – nervous tissue function. Neuromodulation is an evolving therapy that can involve a range of electromagnetic stimuli such as a magnetic field (rTMS), an electric current, or a drug instilled directly in the subdural space. Emerging applications involve targeted introduction of genes or gene regulators and light (optogenetics), and by 2014, these had been at minimum demonstrated in mammalian models, or first-in-human data had been acquired. The most clinical experience has been with electrical stimulation.

An analgesic adjuvant is a medication that is typically used for indications other than pain control but provides control of pain (analgesia) in some painful diseases. This is often part of multimodal analgesia, where one of the intentions is to minimize the need for opioids.

Peripheral mononeuropathy is a nerve related disease where a single nerve, that is used to transport messages from the brain to the peripheral body, is diseased or damaged. Peripheral neuropathy is a general term that indicates any disorder of the peripheral nervous system. The name of the disorder itself can be broken down in order to understand this better; peripheral: in regard to peripheral neuropathy, refers to outside of the brain and spinal cord; neuro: means nerve related; -pathy; means disease. Peripheral mononeuropathy is a disorder that links to Peripheral Neuropathy, as it only effects a single peripheral nerve rather than several damaged or diseased nerves throughout the body. Healthy peripheral nerves are able to “carry messages from the brain and spinal cord to muscles, organs, and other body tissues”.

A nerve decompression is a neurosurgical procedure to relieve chronic, direct pressure on a nerve to treat nerve entrapment, a pain syndrome characterized by severe chronic pain and muscle weakness. In this way a nerve decompression targets the underlying pathophysiology of the syndrome and is considered a first-line surgical treatment option for peripheral nerve pain. Despite treating the underlying cause of the disease, the symptoms may not be fully reversible as delays in diagnosis can allow permanent damage to occur to the nerve and surrounding microvasculature. Traditionally only nerves accessible with open surgery have been good candidates, however innovations in laparoscopy and nerve-sparing techniques made nearly all nerves in the body good candidates, as surgical access is no longer a barrier.

References

  1. ↑ DiBonaventura, Marco D.; Sadosky, Alesia; Concialdi, Kristen; Hopps, Markay; Kudel, Ian; Parsons, Bruce; Cappelleri, Joseph C.; Hlavacek, Patrick; Alexander, Andrea H.; Stacey, Brett R.; Markman, John D.; Farrar, John T. (2017). "The prevalence of probable neuropathic pain in the US: results from a multimodal general-population health survey". Journal of Pain Research. 10: 2525–2538. doi: 10.2147/JPR.S127014 . PMC   5677393 . PMID   29138590.
  2. ↑ "Terminology Pain terms and definitions". Archived from the original on 13 January 2015. Retrieved 15 Nov 2023.
  3. 1 2 3 Kaur, Jaskirat; Ghosh, Shampa; Sahani, Asish Kumar; Sinha, Jitendra Kumar (June 2019). "Mental imagery training for treatment of central neuropathic pain: a narrative review". Acta Neurologica Belgica. 119 (2): 175–186. doi:10.1007/s13760-019-01139-x. PMID   30989503. S2CID   115153320.
  4. ↑ De Courcy, Jonathan; Liedgens, Hiltrud; Obradovic, Marko; Holbrook, Tim; Jakubanis, Rafal (April 2016). "A burden of illness study for neuropathic pain in Europe". ClinicoEconomics and Outcomes Research. 8: 113–126. doi: 10.2147/CEOR.S81396 . PMC   4853004 . PMID   27217785.
  5. ↑ Torrance N, Smith BH, Bennett MI, Lee AJ (April 2006). "The epidemiology of chronic pain of predominantly neuropathic origin. Results from a general population survey". J Pain. 7 (4): 281–9. doi: 10.1016/j.jpain.2005.11.008 . PMID   16618472.
  6. ↑ Bouhassira, Didier; Lantéri-Minet, Michel; Attal, Nadine; Laurent, Bernard; Touboul, Chantal (June 2008). "Prevalence of chronic pain with neuropathic characteristics in the general population" (PDF). Pain. 136 (3): 380–387. doi:10.1016/j.pain.2007.08.013. PMID   17888574. S2CID   599627.
  7. ↑ Freynhagen, R; Bennett, M I (12 August 2009). "Diagnosis and management of neuropathic pain". BMJ. 339 (aug12 1): b3002. doi:10.1136/bmj.b3002. PMC   6130809 . PMID   19675082.
  8. ↑ Fabry, Vincent; Gerdelat, Angélique; Acket, Blandine; Cintas, Pascal; Rousseau, Vanessa; Uro-Coste, Emmanuelle; Evrard, Solène M.; Pavy-Le Traon, Anne (5 May 2020). "Which Method for Diagnosing Small Fiber Neuropathy?". Frontiers in Neurology. 11: 342. doi: 10.3389/fneur.2020.00342 . PMC   7214721 . PMID   32431663.
  9. ↑ Porubcin, Michal G.; Novak, Peter (17 April 2020). "Diagnostic Accuracy of Electrochemical Skin Conductance in the Detection of Sudomotor Fiber Loss". Frontiers in Neurology. 11: 273. doi: 10.3389/fneur.2020.00273 . PMC   7212463 . PMID   32425871.
  10. 1 2 Kaur, Jaskirat; Ghosh, Shampa; Sahani, Asish Kumar; Sinha, Jitendra Kumar (November 2020). "Mental Imagery as a Rehabilitative Therapy for Neuropathic Pain in People With Spinal Cord Injury: A Randomized Controlled Trial". Neurorehabilitation and Neural Repair. 34 (11): 1038–1049. doi:10.1177/1545968320962498. PMID   33040678. S2CID   222300017.
  11. ↑ Baron, Ralf; Binder, Andreas; Wasner, Gunnar (August 2010). "Neuropathic pain: diagnosis, pathophysiological mechanisms, and treatment". The Lancet Neurology. 9 (8): 807–819. doi:10.1016/S1474-4422(10)70143-5. PMID   20650402. S2CID   14267074.
  12. ↑ Portenoy RK (1989). "Painful polyneuropathy". Neurol Clin. 7 (2): 265–88. doi:10.1016/S0733-8619(18)30813-2. PMID   2566901.
  13. 1 2 Vaillancourt PD, Langevin HM (1999). "Painful peripheral neuropathies". Med. Clin. North Am. 83 (3): 627–42, vi. doi:10.1016/S0025-7125(05)70127-9. PMID   10386118.
  14. ↑ Chemotherapy-induced Peripheral Neuropathy Fact Sheet, Retrieved on 29 December 2008
  15. ↑ Archived 2009-07-08 at the Wayback Machine Cancerbackup, Macmillan Cancer Support, Peripheral neuropathy, Retrieved on 29 December 2008
  16. ↑ Hooten, W. Michael (July 2016). "Chronic Pain and Mental Health Disorders". Mayo Clinic Proceedings. 91 (7): 955–970. doi: 10.1016/j.mayocp.2016.04.029 . PMID   27344405.
  17. ↑ Bravo, Lidia; Llorca-Torralba, Meritxell; Suárez-Pereira, Irene; Berrocoso, Esther (August 2020). "Pain in neuropsychiatry: Insights from animal models". Neuroscience & Biobehavioral Reviews. 115: 96–115. doi:10.1016/j.neubiorev.2020.04.029. PMID   32437745. S2CID   218580755.
  18. ↑ Sadosky, Alesia; Schaefer, Caroline; Mann, Rachael; Daniel, Shoshana; Parsons, Bruce; Tuchman, Michael; Anschel, Alan; Stacey, Brett R; Nalamachu, Srinivas; Nieshoff, Edward (October 2014). "Pain severity and the economic burden of neuropathic pain in the United States: BEAT Neuropathic Pain Observational Study". ClinicoEconomics and Outcomes Research. 6: 483–496. doi: 10.2147/CEOR.S63323 . PMC   4218900 . PMID   25378940.
  19. ↑ Egli, Mark; Koob, George F.; Edwards, Scott (November 2012). "Alcohol dependence as a chronic pain disorder". Neuroscience & Biobehavioral Reviews. 36 (10): 2179–2192. doi:10.1016/j.neubiorev.2012.07.010. PMC   3612891 . PMID   22975446.
  20. ↑ Alford, Daniel P.; German, Jacqueline S.; Samet, Jeffrey H.; Cheng, Debbie M.; Lloyd-Travaglini, Christine A.; Saitz, Richard (May 2016). "Primary Care Patients with Drug Use Report Chronic Pain and Self-Medicate with Alcohol and Other Drugs". Journal of General Internal Medicine. 31 (5): 486–491. doi:10.1007/s11606-016-3586-5. PMC   4835374 . PMID   26809204.
  21. ↑ Dueñas, María; Ojeda, Begoña; Salazar, Alejandro; Mico, Juan Antonio; Failde, Inmaculada (28 June 2016). "A review of chronic pain impact on patients, their social environment and the health care system". Journal of Pain Research. 9: 457–467. doi: 10.2147/JPR.S105892 . PMC   4935027 . PMID   27418853.
  22. ↑ Petrosky, Emiko; Harpaz, Rafael; Fowler, Katherine A.; Bohm, Michele K.; Helmick, Charles G.; Yuan, Keming; Betz, Carter J. (2 October 2018). "Chronic Pain Among Suicide Decedents, 2003 to 2014: Findings From the National Violent Death Reporting System". Annals of Internal Medicine. 169 (7): 448–455. doi:10.7326/M18-0830. PMC   6913029 . PMID   30208405.
  23. ↑ Bennetto, Luke; Patel, Nikunj K; Fuller, Geraint (27 January 2007). "Trigeminal neuralgia and its management". BMJ. 334 (7586): 201–205. doi:10.1136/bmj.39085.614792.BE. PMC   1782012 . PMID   17255614.
  24. ↑ Staff, Nathan P.; Grisold, Anna; Grisold, Wolfgang; Windebank, Anthony J. (June 2017). "Chemotherapy-induced peripheral neuropathy: A current review: CIPN". Annals of Neurology. 81 (6): 772–781. doi:10.1002/ana.24951. PMC   5656281 . PMID   28486769.
  25. ↑ Dworkin RH, O'Connor AB, Backonja M, et al. (2007). "Pharmacologic management of neuropathic pain: evidence-based recommendations". Pain. 132 (3): 237–51. doi:10.1016/j.pain.2007.08.033. PMID   17920770. S2CID   9333155.
  26. 1 2 3 4 Wiffen, PJ; Derry, S; Bell, RF; Rice, AS; Tölle, TR; Phillips, T; Moore, RA (9 June 2017). "Gabapentin for chronic neuropathic pain in adults". The Cochrane Database of Systematic Reviews. 6 (2): CD007938. doi:10.1002/14651858.CD007938.pub4. PMC   6452908 . PMID   28597471.
  27. 1 2 3 Dworkin, RH; O'Connor, AB; Audette, J; Baron, R; Gourlay, GK; Haanpää, ML; Kent, JL; Krane, EJ; Lebel, AA; Levy, RM; Mackey, SC; Mayer, J; Miaskowski, C; Raja, SN; Rice, AS; Schmader, KE; Stacey, B; Stanos, S; Treede, RD; Turk, DC; Walco, GA; Wells, CD (Mar 2010). "Recommendations for the pharmacological management of neuropathic pain: an overview and literature update". Mayo Clinic Proceedings. 85 (3 Suppl): S3-14. doi:10.4065/mcp.2009.0649. PMC   2844007 . PMID   20194146.
  28. ↑ Derry, Sheena; Bell, Rae Frances; Straube, Sebastian; Wiffen, Philip J.; Aldington, Dominic; Moore, R. Andrew (2019-01-23). "Pregabalin for neuropathic pain in adults". The Cochrane Database of Systematic Reviews. 1 (1): CD007076. doi:10.1002/14651858.CD007076.pub3. ISSN   1469-493X. PMC   6353204 . PMID   30673120.
  29. ↑ "Pharmacological treatment for all neuropathic pain except trigeminal neuralgia". NICE Guidance CG173. 2013.
  30. ↑ "Neuropathic pain in adults: pharmacological management in non-specialist settings | Guidance and guidelines | NICE". www.nice.org.uk. 20 November 2013.
  31. ↑ Al-Quliti, Khalid W. (April 2015). "Update on neuropathic pain treatment for trigeminal neuralgia: The pharmacological and surgical options". Neurosciences. 20 (2): 107–114. doi:10.17712/nsj.2015.2.20140501. PMC   4727618 . PMID   25864062.
  32. ↑ Wiffen, Philip J; Derry, Sheena; Moore, R Andrew (2013). "Lamotrigine for chronic neuropathic pain and fibromyalgia in adults". Cochrane Database of Systematic Reviews. 2019 (5): CD006044. doi:10.1002/14651858.CD006044.pub4. PMC   6485508 . PMID   24297457.
  33. ↑ Dowell, D; Haegerich, TM; Chou, R (18 March 2016). "CDC Guideline for Prescribing Opioids for Chronic Pain - United States, 2016". MMWR. Recommendations and Reports. 65 (1): 1–49. doi: 10.15585/mmwr.rr6501e1 . PMC   6390846 . PMID   26987082. Several guidelines agree that first- and second-line drugs for neuropathic pain include anticonvulsants (gabapentin or pregabalin), tricyclic antidepressants, and SNRIs
  34. 1 2 McNicol, ED; Midbari, A; Eisenberg, E (29 August 2013). "Opioids for neuropathic pain". The Cochrane Database of Systematic Reviews. 2019 (8): CD006146. doi:10.1002/14651858.CD006146.pub2. PMC   6353125 . PMID   23986501.
  35. ↑ Davis AM, Inturrisi CE (1999). "d-Methadone blocks morphine tolerance and N-methyl-D-aspartate-induced hyperalgesia". J. Pharmacol. Exp. Ther. 289 (2): 1048–53. PMID   10215686.
  36. ↑ Bruera E, Palmer JL, Bosnjak S, et al. (2004). "Methadone versus morphine as a first-line strong opioid for cancer pain: a randomized, double-blind study". J. Clin. Oncol. 22 (1): 185–92. doi: 10.1200/JCO.2004.03.172 . PMID   14701781.
  37. ↑ Derry, Sheena; Stannard, Cathy; Cole, Peter; Wiffen, Philip J.; Knaggs, Roger; Aldington, Dominic; Moore, R. Andrew (2016-10-11). "Fentanyl for neuropathic pain in adults". The Cochrane Database of Systematic Reviews. 10 (5): CD011605. doi:10.1002/14651858.CD011605.pub2. PMC   6457928 . PMID   27727431.
  38. ↑ Volkow, Nora D.; McLellan, A. Thomas (31 March 2016). "Opioid Abuse in Chronic Pain — Misconceptions and Mitigation Strategies". New England Journal of Medicine. 374 (13): 1253–1263. doi: 10.1056/NEJMra1507771 . PMID   27028915.
  39. ↑ Nicholas, Michael K.; Asghari, Ali; Sharpe, Louise; Beeston, Lee; Brooker, Charles; Glare, Paul; Martin, Rebecca; Molloy, Allan; Wrigley, Paul J. (March 2020). "Reducing the use of opioids by patients with chronic pain: an effectiveness study with long-term follow-up". Pain. 161 (3): 509–519. doi:10.1097/j.pain.0000000000001763. PMID   31764391. S2CID   208276026.
  40. ↑ McPherson, Sterling; Lederhos Smith, Crystal; Dobscha, Steven K.; Morasco, Benjamin J.; Demidenko, Michael I.; Meath, Thomas H.A.; Lovejoy, Travis I. (October 2018). "Changes in pain intensity after discontinuation of long-term opioid therapy for chronic noncancer pain". Pain. 159 (10): 2097–2104. doi:10.1097/j.pain.0000000000001315. PMC   6993952 . PMID   29905648.
  41. ↑ Colloca, Luana; Ludman, Taylor; Bouhassira, Didier; Baron, Ralf; Dickenson, Anthony H.; Yarnitsky, David; Freeman, Roy; Truini, Andrea; Attal, Nadine; Finnerup, Nanna B.; Eccleston, Christopher; Kalso, Eija; Bennett, David L.; Dworkin, Robert H.; Raja, Srinivasa N. (21 December 2017). "Neuropathic pain". Nature Reviews Disease Primers. 3 (1): 17002. doi:10.1038/nrdp.2017.2. PMC   5371025 . PMID   28205574.
  42. ↑ Mittal, SO; Safarpour, D; Jabbari, B (February 2016). "Botulinum Toxin Treatment of Neuropathic Pain". Seminars in Neurology. 36 (1): 73–83. doi:10.1055/s-0036-1571953. PMID   26866499. S2CID   41120474.
  43. ↑ Mücke M, Phillips T, Radbruch L, Petzke F, Häuser W (March 2018). "Cannabis-based medicines for chronic neuropathic pain in adults". Cochrane Database Syst Rev (Systematic review). 3 (7): CD012182. doi:10.1002/14651858.CD012182.pub2. PMC   6494210 . PMID   29513392.
  44. ↑ Krames ES (2006). "Neuromodulatory devices are part of our "Tools of the Trade"". Pain Med. 7: S3–5. doi: 10.1111/j.1526-4637.2006.00116.x .
  45. ↑ Bittar, Richard G.; Kar-Purkayastha, Ishani; Owen, Sarah L.; Bear, Renee E.; Green, Alex; Wang, ShouYan; Aziz, Tipu Z. (June 2005). "Deep brain stimulation for pain relief: A meta-analysis". Journal of Clinical Neuroscience. 12 (5): 515–519. doi:10.1016/j.jocn.2004.10.005. PMID   15993077. S2CID   24246117.
  46. ↑ Oh MY, Abosch A, Kim SH, Lang AE, Lozano AM (2002). "Long-term hardware-related complications of deep brain stimulation". Neurosurgery. 50 (6): 1268–74, discussion 1274–6. doi:10.1097/00006123-200206000-00017. PMID   12015845. S2CID   36904630.
  47. ↑ Brown JA, Pilitsis JG. Motor Cortex Stimulation Pain Medicine 2006; 7:S140.
  48. ↑ Osenbach, R. Neurostimulation for the Treatment of Intractable Facial Pain Pain Medicine 2006; 7:S126
  49. ↑ Turner JA, Loeser JD, Deyo RA, Sanders SB (2004). "Spinal cord stimulation for patients with failed back surgery syndrome or complex regional pain syndrome: a systematic review of effectiveness and complications". Pain. 108 (1–2): 137–47. doi:10.1016/j.pain.2003.12.016. PMID   15109517. S2CID   16722691.
  50. ↑ Nelson KA, Park KM, Robinovitz E, Tsigos C, Max MB (1997). "High-dose oral dextromethorphan versus placebo in painful diabetic neuropathy and postherpetic neuralgia". Neurology. 48 (5): 1212–8. doi:10.1212/WNL.48.5.1212. PMID   9153445. S2CID   25663595.
  51. ↑ Camerin, Luisa; Maleeva, Galyna; Gomila-Juaneda, Alexandre; Suárez-Pereira, Irene; Matera, Carlo; Prischich, Davia; Opar, Ekin; Riefolo, Fabio; Berrocoso, Esther; Gorostiza, Pau (2024-06-18). "Photoswitchable carbamazepine analogs for non‐invasive neuroinhibition in vivo". Angewandte Chemie International Edition. doi: 10.1002/anie.202403636 . ISSN   1433-7851.
  52. ↑ Lynch SS, Cheng CM, Yee JL (2006). "Intrathecal ziconotide for refractory chronic pain". Ann Pharmacother. 40 (7–8): 1293–300. doi:10.1345/aph.1G584. PMID   16849624. S2CID   1159955.
  53. ↑ Russo, Marc A.; Baron, Ralf; Dickenson, Anthony H.; Kern, Kai-Uwe; Santarelli, Danielle M. (17 May 2022). "Ambroxol for neuropathic pain: hiding in plain sight?". Pain. 164 (1): 3–13. doi:10.1097/j.pain.0000000000002693. PMID   35580314. S2CID   248858603.
  54. 1 2 Tadokoro, Takahiro; Bravo-Hernandez, Mariana; Agashkov, Kirill; Kobayashi, Yoshiomi; et al. (May 2022). "Precision spinal gene delivery-induced functional switch in nociceptive neurons reverses neuropathic pain". Molecular Therapy. 30 (8): 2722–2745. doi:10.1016/j.ymthe.2022.04.023. PMC   9372322 . PMID   35524407. S2CID   248553626.
  55. 1 2 Nolano M, Simone DA, Wendelschafer-Crabb G, Johnson T, Hazen E, Kennedy WR (1999). "Topical capsaicin in humans: parallel loss of epidermal nerve fibers and pain sensation". Pain. 81 (1–2): 135–45. doi:10.1016/S0304-3959(99)00007-X. PMID   10353501. S2CID   8952555.
  56. ↑ Derry, Sheena; Moore, R Andrew (12 September 2012). "Topical capsaicin (low concentration) for chronic neuropathic pain in adults". Cochrane Database of Systematic Reviews. 2019 (9): CD010111. doi:10.1002/14651858.CD010111. PMC   6540838 . PMID   22972149.
  57. 1 2 Lipinski LJ, Spinner RJ (October 2014). "Neurolysis, neurectomy, and nerve repair/reconstruction for chronic pain". Neurosurg Clin N Am. 25 (4): 777–87. doi:10.1016/j.nec.2014.07.002. PMID   25240664.
  58. 1 2 Kay J, de Sa D, Morrison L, Fejtek E, Simunovic N, Martin HD, Ayeni OR (December 2017). "Surgical Management of Deep Gluteal Syndrome Causing Sciatic Nerve Entrapment: A Systematic Review". Arthroscopy. 33 (12): 2263–2278.e1. doi:10.1016/j.arthro.2017.06.041. PMID   28866346.
  59. 1 2 ElHawary H, Barone N, Baradaran A, Janis JE (February 2022). "Efficacy and Safety of Migraine Surgery: A Systematic Review and Meta-analysis of Outcomes and Complication Rates". Ann Surg. 275 (2): e315–e323. doi:10.1097/SLA.0000000000005057. PMID   35007230.
  60. ↑ Giulioni C, Pirola GM, Maggi M, Pitoni L, Fuligni D, Beltrami M, Palantrani V, De Stefano V, Maurizi V, Castellani D, Galosi AB (March 2024). "Pudendal Nerve Neurolysis in Patients Afflicted With Pudendal Nerve Entrapment: A Systematic Review of Surgical Techniques and Their Efficacy". Int Neurourol J. 28 (1): 11–21. doi:10.5213/inj.2448010.005. PMC   10990758 . PMID   38569616.
  61. ↑ Lu VM, Burks SS, Heath RN, Wolde T, Spinner RJ, Levi AD (January 2021). "Meralgia paresthetica treated by injection, decompression, and neurectomy: a systematic review and meta-analysis of pain and operative outcomes". J Neurosurg. 135 (3): 912–922. doi:10.3171/2020.7.JNS202191. PMID   33450741.
  62. ↑ Lundborg G, Dahlin LB (May 1996). "Anatomy, function, and pathophysiology of peripheral nerves and nerve compression". Hand Clin. 12 (2): 185–93. PMID   8724572.
  63. ↑ Mackinnon SE (May 2002). "Pathophysiology of nerve compression". Hand Clin. 18 (2): 231–41. doi:10.1016/s0749-0712(01)00012-9. PMID   12371026.
  64. ↑ Louie D, Earp B, Blazar P (September 2012). "Long-term outcomes of carpal tunnel release: a critical review of the literature". Hand (N Y). 7 (3): 242–6. doi:10.1007/s11552-012-9429-x. PMC   3418353 . PMID   23997725.
  65. ↑ Sun J, Wang Y, Zhang X, Zhu S, He H (October 2020). "Prevalence of peripheral neuropathy in patients with diabetes: A systematic review and meta-analysis". Prim Care Diabetes. 14 (5): 435–444. doi:10.1016/j.pcd.2019.12.005. PMID   31917119.
  66. 1 2 Xu L, Sun Z, Casserly E, Nasr C, Cheng J, Xu J (June 2022). "Advances in Interventional Therapies for Painful Diabetic Neuropathy: A Systematic Review". Anesth Analg. 134 (6): 1215–1228. doi:10.1213/ANE.0000000000005860. PMC   9124666 . PMID   35051958.
  67. 1 2 Tu Y, Lineaweaver WC, Chen Z, Hu J, Mullins F, Zhang F (March 2017). "Surgical Decompression in the Treatment of Diabetic Peripheral Neuropathy: A Systematic Review and Meta-analysis". J Reconstr Microsurg. 33 (3): 151–157. doi:10.1055/s-0036-1594300. PMID   27894152.
  68. ↑ Dellon AL (February 1988). "A cause for optimism in diabetic neuropathy". Ann Plast Surg. 20 (2): 103–5. doi:10.1097/00000637-198802000-00001. PMID   3355053.
  69. 1 2 Sessions J, Nickerson DS (March 2014). "Biologic Basis of Nerve Decompression Surgery for Focal Entrapments in Diabetic Peripheral Neuropathy". J Diabetes Sci Technol. 8 (2): 412–418. doi:10.1177/1932296814525030. PMC   4455405 . PMID   24876595.
  70. ↑ Dellon AL (October 2014). "Susceptibility of nerve in diabetes to compression: implications for pain treatment". Plast Reconstr Surg. 134 (4 Suppl 2): 142S–150S. doi:10.1097/PRS.0000000000000668. PMID   25254997.
  71. ↑ Fadel ZT, Imran WM, Azhar T (August 2022). "Lower Extremity Nerve Decompression for Diabetic Peripheral Neuropathy: A Systematic Review and Meta-analysis". Plast Reconstr Surg Glob Open. 10 (8): e4478. doi:10.1097/GOX.0000000000004478. PMC   9390809 . PMID   35999882.
  72. ↑ Boyd A, Bleakley C, Hurley DA, Gill C, Hannon-Fletcher M, Bell P, McDonough S (April 2019). "Herbal medicinal products or preparations for neuropathic pain". Cochrane Database Syst Rev (Systematic review). 4 (5): CD010528. doi:10.1002/14651858.CD010528.pub4. PMC   6445324 . PMID   30938843.
  73. 1 2 Foster TS (2007). "Efficacy and safety of alpha-lipoic acid supplementation in the treatment of symptomatic diabetic neuropathy". Diabetes Educ. 33 (1): 111–7. doi:10.1177/0145721706297450. PMID   17272797. S2CID   22801230. ALA appears to improve neuropathic symptoms and deficits when administered via parenteral supplementation over a 3-week period. Oral treatment with ALA appears to have more conflicting data whether it improves sensory symptoms or just neuropathic deficits alone.
  74. ↑ Ziegler D, Ametov A, Barinov A, et al. (2006). "Oral treatment with alpha-lipoic acid improves symptomatic diabetic polyneuropathy: the SYDNEY 2 trial". Diabetes Care. 29 (11): 2365–70. doi: 10.2337/dc06-1216 . PMID   17065669.
  75. ↑ Patton LL, Siegel MA, Benoliel R, De Laat A (2007). "Management of burning mouth syndrome: systematic review and management recommendations". Oral Surg Oral Med Oral Pathol Oral Radiol Endod. 103 Suppl: S39.e1–13. doi:10.1016/j.tripleo.2006.11.009. PMID   17379153.
  76. ↑ Stracke H, Lindemann A, Federlin K (1996). "A benfotiamine-vitamin B combination in treatment of diabetic polyneuropathy". Exp. Clin. Endocrinol. Diabetes. 104 (4): 311–6. doi:10.1055/s-0029-1211460. PMID   8886748.
  77. ↑ Thornalley PJ (2005). "The potential role of thiamine (vitamin B(1)) in diabetic complications". Curr Diabetes Rev. 1 (3): 287–98. doi:10.2174/157339905774574383. PMID   18220605.
  78. ↑ Freemon, Frank R. (1994). "Galen's ideas on neurological function". J Hist Neurosci. 3 (4): 263–71. doi:10.1080/09647049409525619. PMID   11618827.
  79. ↑ Heydari, Mojtaba; Shams, Mesbah; Hashempur, Mohammad Hashem; Zargaran, Arman; Dalfardi, Behnam; Borhani-Haghighi, Afshin (2015). "The origin of the concept of neuropathic pain in Early Medieval Persia (9th–12th century CE)". Acta medico-historica Adriatica. 13 (Suppl 2): 9–22. PMID   26966748. S2CID   30398883.
  80. ↑ Scadding, JW (March 2004). "Treatment of neuropathic pain: historical aspects". Pain Medicine. 5 (Suppl 1): S3-8. doi: 10.1111/j.1526-4637.2004.04018.x . PMID   14996226.
  81. ↑ Gritsch, Simon; Bali, Kiran Kumar; Kuner, Rohini; Vardeh, Daniel (January 2016). "Functional characterization of a mouse model for central post-stroke pain". Molecular Pain. 12: 174480691662904. doi:10.1177/1744806916629049. PMC   4956143 . PMID   27030713.
  82. ↑ Costigan, Michael; Scholz, Joachim; Woolf, Clifford J. (1 June 2009). "Neuropathic Pain: A Maladaptive Response of the Nervous System to Damage". Annual Review of Neuroscience. 32 (1): 1–32. doi:10.1146/annurev.neuro.051508.135531. PMC   2768555 . PMID   19400724.
  83. ↑ Manion, John; Waller, Matthew A.; Clark, Teleri; Massingham, Joshua N.; Neely, G. Gregory (20 December 2019). "Developing Modern Pain Therapies". Frontiers in Neuroscience. 13: 1370. doi: 10.3389/fnins.2019.01370 . PMC   6933609 . PMID   31920521.
  84. ↑ Henderson, L. A.; Peck, C. C.; Petersen, E. T.; Rae, C. D.; Youssef, A. M.; Reeves, J. M.; Wilcox, S. L.; Akhter, R.; Murray, G. M.; Gustin, S. M. (24 April 2013). "Chronic Pain: Lost Inhibition?". Journal of Neuroscience. 33 (17): 7574–7582. doi:10.1523/JNEUROSCI.0174-13.2013. PMC   6619566 . PMID   23616562.
  85. ↑ Ji, Ru-Rong; Donnelly, Christopher R.; Nedergaard, Maiken (November 2019). "Astrocytes in chronic pain and itch". Nature Reviews Neuroscience. 20 (11): 667–685. doi:10.1038/s41583-019-0218-1. PMC   6874831 . PMID   31537912.
  86. ↑ Ji, Ru-Rong; Chamessian, Alexander; Zhang, Yu-Qiu (4 November 2016). "Pain regulation by non-neuronal cells and inflammation". Science. 354 (6312): 572–577. Bibcode:2016Sci...354..572J. doi:10.1126/science.aaf8924. PMC   5488328 . PMID   27811267.
  87. ↑ Siniscalco, Dario; Giordano, Catia; Rossi, Francesco; Maione, Sabatino; de Novellis, Vito (1 December 2011). "Role of Neurotrophins in Neuropathic Pain". Current Neuropharmacology. 9 (4): 523–529. doi:10.2174/157015911798376208. PMC   3263449 . PMID   22654713.
  88. 1 2 Latremoliere, Alban; Woolf, Clifford J. (September 2009). "Central Sensitization: A Generator of Pain Hypersensitivity by Central Neural Plasticity". The Journal of Pain. 10 (9): 895–926. doi:10.1016/j.jpain.2009.06.012. PMC   2750819 . PMID   19712899.
  89. ↑ Ji, Ru-Rong; Kohno, Tatsuro; Moore, Kimberly A; Woolf, Clifford J (December 2003). "Central sensitization and LTP: do pain and memory share similar mechanisms?". Trends in Neurosciences. 26 (12): 696–705. doi:10.1016/j.tins.2003.09.017. PMID   14624855. S2CID   14214986.
  90. ↑ Truini A, Cruccu G (May 2006). "Pathophysiological mechanisms of neuropathic pain". Neurol. Sci. 27 (Suppl 2): S179–82. doi:10.1007/s10072-006-0597-8. PMID   16688626. S2CID   28736907.
This page is based on this Wikipedia article
Text is available under the CC BY-SA 4.0 license; additional terms may apply.
Images, videos and audio are available under their respective licenses.